ChemoMetec A/S (LON:0DZ0)
London · Delayed Price · Currency is GBP · Price in DKK 417.14
-15.73 (-3.63%)
At close: Feb 9, 2026
ChemoMetec Income Statement
Financials in millions DKK. Fiscal year is July - June.
Millions DKK. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Revenue | 493.12 | 495.57 | 407.35 | 442.27 | 427.16 | 281.13 |
Other Revenue | - | - | 0.52 | 2.13 | 1.23 | - |
| 493.12 | 495.57 | 407.87 | 444.4 | 428.39 | 281.13 | |
Revenue Growth (YoY) | 7.31% | 21.50% | -8.22% | 3.74% | 52.38% | 31.31% |
Cost of Revenue | 21.98 | 30.06 | 40.28 | 32.9 | 44.14 | 27.78 |
Gross Profit | 471.14 | 465.51 | 367.6 | 411.5 | 384.25 | 253.34 |
Selling, General & Admin | 212.12 | 207.46 | 181.42 | 160.47 | 161.36 | 117.71 |
Operating Expenses | 240.06 | 228.99 | 198.63 | 180.94 | 181.4 | 137.32 |
Operating Income | 231.08 | 236.52 | 168.97 | 230.56 | 202.85 | 116.02 |
Interest Expense | -1.34 | -0.63 | -0.18 | -1.09 | -1.52 | -0.92 |
Interest & Investment Income | 0.69 | 5.9 | 8.08 | 2.46 | 0.01 | 0.09 |
Currency Exchange Gain (Loss) | -1.78 | -1.78 | -0.27 | -1.57 | 1.87 | -2.46 |
Other Non Operating Income (Expenses) | 0 | 0 | - | - | 0 | - |
EBT Excluding Unusual Items | 228.65 | 240.01 | 176.59 | 230.36 | 203.22 | 112.73 |
Pretax Income | 228.65 | 240.01 | 176.59 | 230.36 | 203.22 | 112.73 |
Income Tax Expense | 51.62 | 53.61 | 40.3 | 51.69 | 43.75 | 24.38 |
Net Income | 177.03 | 186.41 | 136.28 | 178.67 | 159.47 | 88.35 |
Net Income to Common | 177.03 | 186.41 | 136.28 | 178.67 | 159.47 | 88.35 |
Net Income Growth | 4.70% | 36.78% | -23.72% | 12.04% | 80.49% | 49.34% |
Shares Outstanding (Basic) | 17 | 17 | 17 | 17 | 17 | 17 |
Shares Outstanding (Diluted) | 17 | 17 | 17 | 17 | 17 | 17 |
Shares Change (YoY) | 0.07% | - | - | - | - | 3.23% |
EPS (Basic) | 10.17 | 10.71 | 7.83 | 10.27 | 9.16 | 5.08 |
EPS (Diluted) | 10.17 | 10.71 | 7.83 | 10.27 | 9.16 | 5.08 |
EPS Growth | 4.62% | 36.78% | -23.73% | 12.08% | 80.42% | 44.66% |
Free Cash Flow | 179.23 | 177.58 | 108.06 | 132.97 | 137.76 | 96.65 |
Free Cash Flow Per Share | 10.30 | 10.20 | 6.21 | 7.64 | 7.92 | 5.55 |
Dividend Per Share | 7.000 | 7.000 | 4.000 | 6.000 | - | 4.000 |
Dividend Growth | 75.00% | 75.00% | -33.33% | - | - | 166.67% |
Gross Margin | 95.54% | 93.93% | 90.13% | 92.60% | 89.70% | 90.12% |
Operating Margin | 46.86% | 47.73% | 41.43% | 51.88% | 47.35% | 41.27% |
Profit Margin | 35.90% | 37.61% | 33.41% | 40.20% | 37.23% | 31.43% |
Free Cash Flow Margin | 36.35% | 35.83% | 26.49% | 29.92% | 32.16% | 34.38% |
EBITDA | 244.16 | 247.68 | 178.78 | 244.49 | 216.65 | 129.01 |
EBITDA Margin | 49.51% | 49.98% | 43.83% | 55.02% | 50.57% | 45.89% |
D&A For EBITDA | 13.09 | 11.17 | 9.82 | 13.93 | 13.8 | 12.98 |
EBIT | 231.08 | 236.52 | 168.97 | 230.56 | 202.85 | 116.02 |
EBIT Margin | 46.86% | 47.73% | 41.43% | 51.88% | 47.35% | 41.27% |
Effective Tax Rate | 22.58% | 22.34% | 22.82% | 22.44% | 21.53% | 21.63% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.